Doctors call for balance between drug prices and profits

10/3/2013 | MedPage Today (free registration)

Cystic fibrosis treatment Kalydeco's price tag -- up to $373,000 per patient -- is unsustainable and violates drugmakers' responsibility to balance patient well-being with profit motives, three doctors write in the Journal of the American Medical Association. "The vast majority of patients cannot afford this financial burden and transferring the cost to private or federal insurers does not obviate the underlying problem -- an unsustainable pricing structure," the doctors write. Robert Beall, CEO of the Cystic Fibrosis Foundation, which invested in the drug's development, agrees that there is a need to strike a balance between patient needs and recovering the high costs of drug development.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC